[OSUCCC] A five-year, $3.46 million grant from the National Cancer Institute was awarded to The Ohio State University Comprehensive Cancer Center (OSUCCC) and the University of California San Francisco (UCSF). The grant will help researchers study why some patients with AML respond to treatment while others don't.

[Blood] Based on preclinical evidence of synergy, researchers conducted a Phase I trial of the BCL-2 inhibitor venetoclax plus standard-dose inotuzumab ozogamicin for adults with relapsed or refractory CD22⁺ acute lymphoblastic leukemia/lymphoblastic lymphoma.

[Blood] Researchers showed that circadian cues coordinated a program of mitochondrial remodeling, metabolic reprogramming, and structural adaptation in primitive HSCs.

[Life Sciences] The authors synthesize emerging strategies for constructing high-fidelity hematopoietic organoids. They detail engineered bone marrow constructs tailored to model osteo-vascular niches and sustain hematopoietic stemness, paired with thymic platforms reconstructing epithelial microenvironments for directed lymphopoiesis.

[Cancer Gene Therapy] Scientists discuss the molecular mechanisms of targeted protein degradation and its therapeutic potential in hematologic malignancies. They summarize recent advances in degradation technologies, and highlight key targets in leukemia, lymphoma, and multiple myeloma.

[Signal Transduction and Targeted Therapy] Researchers identified a novel aged HSC subpopulation characterized by high expression of Baculoviral IAP Repeat Containing 6 (BIRC6), an apoptosis inhibitor. This BIRC6-high subpopulation is markedly expanded in aged mice and recapitulates the hallmarks of HSC aging.

[Blood Advances] This Phase I, open-label, multicenter study enrolled adult patients with relapsed/refractory lymphoma who had exhausted approved therapies. The trial included dose escalation and expansion stages across multiple lymphoma subtypes.

[Blood Advances] Using CRISPR/Cas9-mediated genome engineering in primary human fetal liver-derived HSCs and xenotransplantation in mice, researchers modeled GATA2-deficient myelodysplastic syndrome with acquired STAG2 loss to investigate disease initiation and progression.

[Molecular Therapy] Researchers evaluated the impact of transient p38 MAPK inhibition on genomic integrity during clinically relevant CRISPR-Cas9 editing and showed that this intervention attenuates ex vivo culture-associated stress without increasing detectable genotoxic outcomes.

[Mesoblast Limited] Mesoblast Limited announced that it has received approval from the US FDA to implement a new potency assay, T cell Proliferation Inhibition BioAssay, for release and stability monitoring of all new commercial product lots of its FDA-approved MSC product Ryoncil^® (remestemcel-L-rknd).

[Recordati (GlobeNewswire)] Recordati today announced Dr. Laura Broutier as the winner of the 12^th edition of the International Prize for Scientific Research Arrigo Recordati, dedicated this year to advancing research in pediatric oncology, with a specific focus on sarcomas.

[Scientific Reports] Scientists performed comparative transcriptomic analyses to define and contrast hypoxia responses in MSCs and human dermal fibroblasts (HDFs). Both cell types mounted robust hypoxia-responsive programs; however, MSCs exhibited substantially broader transcriptomic remodeling, with two- to four-fold more differentially expressed genes than HDFs.